alexa Outcomes of Post-Operative Topical Bevacizumab in Prima
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Outcomes of Post-Operative Topical Bevacizumab in Primary Pterygium Surgery: A Case Series

Aditya Sudhalkar* and Anand Sudhalkar
Eye Hospital and Retinal Laser Centre, Baroda, Gujarat, India
Corresponding Author : Dr. Aditya Sudhalkar
Eye Hospital, Baroda, 22 Pratapgunj
Shiv Bungalow, Baroda, Gujarat, India
Tel: +919909917561
E-mail: [email protected]
Received March 28, 2012; Accepted August 22, 2012; Published August 30, 2012
Citation: Sudhalkar A, Sudhalkar A (2012) Outcomes of Post-Operative Topical Bevacizumab in Primary Pterygium Surgery: A Case Series. J Clin Exp Ophthalmol 3:243. doi:10.4172/2155-9570.1000243
Copyright: © 2012 Sudhalkar A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Background: To determine the efficacy and tolerability of topical bevacizumab as an postoperative adjunct in reduction of recurrence following primary pterygium surgery with conjunctival graft at a two year follow up. Methods: Prospective, non randomized case series. Twenty three consecutive patients with primary pterygium, without any ocular or systemic contraindication to bevacizumab were recruited for the study, with informed consent. All patients underwent primary pterygium excision with rotational conjunctival autograft. Postoperative regimen included plain antibiotic eye drops, preservative-free artificial tears from post operative day 1 and topical bevacizumab (1.25 mg/day), from day 4 postoperatively, q.i.d, for 30 days. Primary outcome measure: Recurrence of pterygium and side effects of treatment. Results: Mean age: 43.12 ± 3.24 years; The mean follow-up was 34.25 ± 2.4 months. Eleven patients were available for the 3 year follow up. None of the patients had a recurrence till the end of follow up. Post operative sequelae of surgery included dellen (2), hyperemia (1) and foreign body sensation (4), all managed. No side effects of topical therapy were noted (dellen occurred before starting bevacizumab therapy). Conclusion: Topical bevacizumab is a potentially useful, convenient and safe therapy as an adjuvant to pterygium surgery. Its safety and efficacy can be further verified with the help of a randomized trial.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version